103 related articles for article (PubMed ID: 10635299)
1. [Molecular biology of ovarian cancer].
Tanaka K
Gan To Kagaku Ryoho; 1999 Dec; 26(14):2162-7. PubMed ID: 10635299
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of prognostic factors in gynecological cancer examined by molecular biological study].
Nagai N
Gan To Kagaku Ryoho; 1996 Jul; 23(8):1004-9. PubMed ID: 8687214
[TBL] [Abstract][Full Text] [Related]
3. Concurrent abnormal expression of erbB-2, myc and ras genes is associated with poor outcome of ovarian cancer patients.
Katsaros D; Theillet C; Zola P; Louason G; Sanfilippo B; Isaia E; Arisio R; Giardina G; Sismondi P
Anticancer Res; 1995; 15(4):1501-10. PubMed ID: 7654038
[TBL] [Abstract][Full Text] [Related]
4. TP53 and ovarian cancer.
Schuijer M; Berns EM
Hum Mutat; 2003 Mar; 21(3):285-91. PubMed ID: 12619114
[TBL] [Abstract][Full Text] [Related]
5. The role of p53 mutation in BRCA1-associated ovarian cancer.
Rose SL; Buller RE
Minerva Ginecol; 2002 Jun; 54(3):201-9. PubMed ID: 12063435
[TBL] [Abstract][Full Text] [Related]
6. [Genetic alterations in the genesis and development of ovarian cancer].
Okamoto A; Yokoyama S; Terashima Y
Gan To Kagaku Ryoho; 1992 Oct; 19(12):1971-6. PubMed ID: 1358031
[TBL] [Abstract][Full Text] [Related]
7. Mutational spectrum of p53 mutations in primary breast and ovarian tumors.
Feki A; Irminger-Finger I
Crit Rev Oncol Hematol; 2004 Nov; 52(2):103-16. PubMed ID: 15501075
[TBL] [Abstract][Full Text] [Related]
8. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.
Buller RE; Lallas TA; Shahin MS; Sood AK; Hatterman-Zogg M; Anderson B; Sorosky JI; Kirby PA
Clin Cancer Res; 2001 Apr; 7(4):831-8. PubMed ID: 11309330
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
10. [Genetic testing of BRCA1 for familial ovarian cancers].
Takano M; Aida H; Tsuneki I; Hasegawa I; Takakuwa K; Tanaka K
Gan To Kagaku Ryoho; 1997 Feb; 24(4):439-42. PubMed ID: 9063481
[TBL] [Abstract][Full Text] [Related]
11. Amplifications of proto-oncogenes in ovarian carcinoma.
Bian M; Fan Q; Huang S; Ma J; Lang J
Chin Med J (Engl); 1995 Nov; 108(11):844-8. PubMed ID: 8585978
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 and p53 protein expression in cultured ovarian surface epithelial cells derived from women with and without a BRCA1 germline mutation.
Piek JM; Dorsman JC; Massuger LF; Ansink AC; Weegenaar J; Shvarts A; Kenemans P; Verheijen RH
Arch Gynecol Obstet; 2006 Oct; 274(6):327-31. PubMed ID: 16826413
[TBL] [Abstract][Full Text] [Related]
13. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
[TBL] [Abstract][Full Text] [Related]
14. Molecular biology of human ovarian cancer.
Chow SN; Chien CH; Chen CT
Int Surg; 1996; 81(2):152-7. PubMed ID: 8912082
[TBL] [Abstract][Full Text] [Related]
15. No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers.
Aghmesheh M; Nesland JM; Kaern J; Dorum A; Edwards L; Byth K; Friedlander M; Jackson P; Tucker KM; Russell PJ
Gynecol Oncol; 2004 Dec; 95(3):430-6. PubMed ID: 15581943
[TBL] [Abstract][Full Text] [Related]
16. Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
Patmasiriwat P; Bhothisuwan K; Sinilnikova OM; Chopin S; Methakijvaroon S; Badzioch M; Padungsutt P; Vattanaviboon P; Vattanasapt V; Szabo C; Saunders GF; Goldgar D; Lenoir GM
Hum Mutat; 2002 Sep; 20(3):230. PubMed ID: 12203997
[TBL] [Abstract][Full Text] [Related]
17. Gene expression and prognostic significance in ovarian cancer.
Tammela J; Odunsi K
Minerva Ginecol; 2004 Dec; 56(6):495-502. PubMed ID: 15729202
[TBL] [Abstract][Full Text] [Related]
18. Implication of BRCA1 gene in breast cancer.
Kachhap SK; Ghosh SN
Indian J Exp Biol; 2001 May; 39(5):391-400. PubMed ID: 11510120
[TBL] [Abstract][Full Text] [Related]
19. Antisense inhibition of BRCA1 expression and molecular analysis of hereditary tumors indicate that functional inactivation of the p53 DNA damage response pathway is required for BRCA-associated tumorigenesis.
Reedy MB; Hang T; Gallion H; Arnold S; Smith SA
Gynecol Oncol; 2001 Jun; 81(3):441-6. PubMed ID: 11371136
[TBL] [Abstract][Full Text] [Related]
20. Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP).
Geisler JP; Hatterman-Zogg MA; Rathe JA; Lallas TA; Kirby P; Buller RE
Hum Mutat; 2001 Oct; 18(4):337-44. PubMed ID: 11668617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
